Table 6.
Overview of lipid-based NPs: structure, pH sensitization method, tumor type, and delivered drug.
| First Author | Publication Year | Structure of NPs | pH Sensitization Method | Tumor Type | Drug |
|---|---|---|---|---|---|
| Juang [59] | 2019 | lipid-PEG | pH-labile imide linkers | HCT116 colon carcinoma | Irinotecan and microRNA |
| Li [69] | 2017 | TF-PEG-GMS | pH-labile hydrazone linkers | A549/DTX lung cancer cell line | Docetaxel and Baicalin |
| Li [71] | 2019 | LDL-OA | pH-labile hydrazone linkers | 4T1 breast carcinoma cell line | Doxorubicin |
| Sun [111] | 2021 | DSPE-PEG | pH-triggered structural changes | LNCaP-AI prostate carcinoma | Doxorubicin |
| Tan [112] | 2017 | PAA-OA | pH-labile oleic acid linkers | A549 NSLC cell line | Erlotinib |
| Men [92] | 2020 | lipid-HA-PBAE | pH-triggered structural changes | A549 NSLC cell line | Doxorubicin |
| Cavalcante [22] | 2021 | DSPE-PEG-OA | pH-labile oleic acid linkers | 4T1 breast carcinoma cell line | Doxorubicin |
| Li [67] | 2017 | DSPE-PEG | pH-labile imine linkers | FTC-133 thyroid cancer | Doxorubicin |
| Lo [85] | 2020 | DSPE-PEG | pH-labile oleic acid linkers | SAS squamos carcinoma cell line | Daunorubicin and Irinotecan |
| Ma [90] | 2021 | DSPE-PEG | pH-triggered structural changes | HepG2 liver cancer | hydroxycamptothecin |
| Pang [98] | 2020 | lipid-polymeric NPs | pH-labile dihydrazide linkers | A549 NSLC cell line | Erlotinib |
| Xie [120] | 2018 | DSPE-PEG | pH-labile imine linkers | MCF-7 breast carcinoma cell line | Methotrexate |
Legend: PEG, polyethylene glycol; TF; transferrin; GMS, glyceryl monostearate; PAA, polyacrylic acid; HA, hyaluronic acid; PBAE, poly(b-amino ester; DSPE, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine; OA, oleic acid.